503896256 06/30/2016

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3942906

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
MILLENNIUM PHARMACEUTICALS, INC.	03/19/2015

## **RECEIVING PARTY DATA**

Name:	IMMUNOGEN, INC.
Street Address:	830 WINTER STREET
City:	WALTHAM
State/Country:	MASSACHUSETTS
Postal Code:	02451

### **PROPERTY NUMBERS Total: 1**

Property Type	Number
Patent Number:	7598375

#### **CORRESPONDENCE DATA**

#### Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 6174496500

Email:DOCKET@MCCARTER.COMCorrespondent Name:MCCARTER & ENGLISH, LLPAddress Line 1:265 FRANKLIN STREET

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER: 121162-00001

NAME OF SUBMITTER: STEVEN G. DAVIS

SIGNATURE: /Steven G. Davis/

**DATE SIGNED:** 06/30/2016

#### **Total Attachments: 5**

source=Recordation\_Document\_FINAL#page1.tif source=Recordation\_Document\_FINAL#page2.tif source=Recordation\_Document\_FINAL#page3.tif source=Recordation\_Document\_FINAL#page4.tif

 $source = Recordation\_Document\_FINAL\#page 5.tif$ 

PATENT 503896256 REEL: 039052 FRAME: 0987

#### **MULTI-TARGET AGREEMENT**


This Multi-Target Agreement (this "Agreement") is made effective as of the date of the last signature below (the "Effective Date") by and between ImmunoGen, Inc., a Massachusetts corporation ("ImmunoGen"), with its principal place of business at 830 Winter Street, Waltham, Massachusetts 02451, and Millennium Pharmaceuticals, Inc., a Delaware corporation ("Millennium") and a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, with its principal place of business at 40 Landsdowne Street, Cambridge, Massachusetts 02139. ImmunoGen and Millennium are sometimes each hereinafter referred to individually as a "Party" and collectively as the "Parties."


WHEREAS, Millennium is the owner of or otherwise controls certain rights in Technology relating to certain Antibodies directed to specified Targets and the conjugation of Antibodies with payloads; and

WHEREAS, ImmunoGen is the owner of or otherwise controls certain rights in Technology relating to or otherwise useful in the conjugation of Cytotoxic Compounds to Antibodies; and

WHEREAS, pursuant to the terms and conditions set forth herein, Millennium desires to have access to ImmunoGen's Technology (and associated Patent Rights) for research, discovery and development of ADCs to specified Targets, and ImmunoGen desires to give Millennium such access.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:





## **SCHEDULE B**

# MILLENNIUM PROCESS PATENTS

# Method of Acylating Maytansinoid with Chiral Amino Acids

Australia: Patent No. 2006280146

Canada: Patent No. 2617953

Europe: Patent No. 1913002 (France; Germany; and Great Britain)

Japan: Patent No. 5167130

U.S.A: Patent No. 7,598,375

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

IMMUNOGEN, INC.	MILLENNIUM PHARMACEUTICALS, INC.
By: Petry & Allillian	By:
Name: Peter Villiams	Name:
Title: VICE PRESIDENT	Title:
Date: March 20, 2015	Date:

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their duly authorized representatives.

WANKARK COV Little statement in we a see.	IMMUNOGEN,	INC.
---	------------	------

MILLENNIUM PHARMACEUTICALS INC.

By:	Ry. ( MM	
	Name: Ch. Birrochi	2000
Nation:	Tida Pagions	
Title:	Date: March 19, 2015	20000
Date:	LANG.	,,,,,,,,,,,

PATENT REEL: 039052 FRAME: 0992

**RECORDED: 06/30/2016**